Episode 22. Management of Low-Risk MDS

Blood Cancer Talks

Innhold levert av Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

1+ y ago 1:03:46

MP3•Episoder hjem

In this episode, we take a deep dive into low-risk MDS management. We have the privilege of being joined by the esteemed Dr. Mikkael Sekeres. We also explore his invaluable insights gained from his time at FDA ODAC and his latest literary endeavor, "Drugs and the FDA".
Here are the key studies discussed:

1. ASH choosing wisely:
https://www.hematology.org/education/clinicians/guidelines-and-quality-care/choosing-wisely

2. International Consensus Classification (ICC):
https://pubmed.ncbi.nlm.nih.gov/35767897/

3. WHO classification 2022:
https://pubmed.ncbi.nlm.nih.gov/35732829/

4. IPSS-M:
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200008

5. Romiplostim in MDS:
https://pubmed.ncbi.nlm.nih.gov/29396092/

6. Low-dose decitabine vs. low-dose azacItidine in lower-risk MDS:
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200034

7. Luspatercept in MDS:
https://www.nejm.org/doi/full/10.1056/nejmoa1908892

8. Lenalidomide in MDS:

https://ascopubs.org/doi/10.1200/JCO.2015.66.0118

https://pubmed.ncbi.nlm.nih.gov/21753188/

9.Iron chelation therapy in MDS:

https://pubmed.ncbi.nlm.nih.gov/32203980/

52 episoder

#Fitness #Medicine #Rajshekhar Chakraborty and Ashwin Kishtagari #Ashwin Kishtagari #Rajshekhar Chakraborty #Hematology #Cancer #Podcasting Education #Edward Cliff

Episode 22. Management of Low-Risk MDS

Blood Cancer Talks

published 1+ y ago

Del